Antibiotic-Eluting Envelopes to Prevent Cardiac-Implantable Electronic Device Infection: Past, Present, and Future

Kun Xiang 1, John N. Catanzaro 2, Claude Elayi 2, Zerelda Esquer Garrigos 3, Muhammad R. Sohail 4

1. Cardiology, University of Florida College of Medicine, Gainesville, USA 2. Cardiology, University of Florida College of Medicine – Jacksonville, Jacksonville, USA 3. Internal Medicine/Infectious Disease, Mayo Clinic College of Medicine, University of Mississippi Medical Center, Rochester, USA 4. Cardiovascular Infectious Diseases, Baylor College of Medicine, Houston, USA

Corresponding author: Kun Xiang, kun.xiang@medicine.ufl.edu

Abstract

Objective: Cardiac-implantable electronic device (CIED) infections are associated with significant morbidity and mortality. In this review, we describe the risk factors and pathogenesis of CIED infections and review the rationale and the evidence for the use of antibiotic-eluting envelopes (ABEs) in patients at increased risk for CIED infections.

Findings: The majority of CIED infections are caused by staphylococci that involve generator pocket and occur due to contamination of the device or the pocket tissues at the time of implantation. Clinical trials have shown that extending the duration of post-operative systemic antibacterial therapy is not beneficial in reducing CIED infection rate. However, ABEs that reduce device migration after implantation and provide sustained local delivery of prophylactic antibiotics at the pocket site, may provide benefit in reducing infection. Currently, there are two types of commercially available CIED envelope devices in the United States. The first ABE device (TYRX™, Medtronic Inc., Monmouth Junction, NJ) is composed of a synthetic absorbable mesh envelope that elutes minocycline and rifampin and has been shown to reduce CIED pocket infections in a large multi-center randomized clinical trial. The second ABE device (CanGaroo-G™, Aziyo Biologics, Silver Spring, MD) is composed of decellularized extracellular matrix (ECM) and was originally designed to stabilize the device within the pocket, limiting risk for migration or erosion, and providing a substrate for tissue ingrowth in a preclinical study. This device has shown promising results in a preclinical study with local delivery of gentamicin. Compared with artificial materials, such as synthetic surgical mesh, biologic ECM has been shown to foster greater tissue integration and vascular ingrowth, a reduced inflammatory response, and more rapid clearance of bacteria.

Conclusions and Relevance: ABE devices provide sustained local delivery of antibiotics at the generator pocket site and appear beneficial in reducing CIED pocket infections. Given the continued increase in the use of CIED therapy and resultant infectious complications, innovative approaches to infection prevention are critical.

Introduction And Background

Infections are a devastating complication of cardiac-implantable electronic devices (CIED) therapy and are associated with increased morbidity, mortality, and cost. Moreover, reported rates of CIED infection are rising faster even when accounting for the continuous growth in CIED implantation [1]. This might be because of the CIED implantation in patients with multiple risk factors, such as older age and multiple comorbidities [1]. Prevention of CIED-related infection, therefore, is a key consideration in the design and implantation of CIEDs. Evidence-based prophylactic approaches include the use of preoperative antibiotics, thorough surgical skin disinfection, and the implantation of CIED with antibiotic-eluting envelopes [2]. Emerging evidence supports the efficacy of these antibiotic-eluting envelopes that provide high local antibiotic concentrations in the surgical pocket, with minimal systemic exposure [3]. Currently, there are two commercially available CIED envelope devices in the United States. This article reviews the evidence describing the rationale for these antibiotic-eluting envelopes in patients undergoing CIED implantation.

Review

CIED infections: Incidence, costs, and risk factors

In the absence of comprehensive and mandatory registries, the estimates of the incidence of CIED infections in North America mostly rely on observational studies and vary based on study type, CIED type, and follow-

How to cite this article
Xiang K, Catanzaro J N, Elayi C, et al. (February 02, 2021) Antibiotic-Eluting Envelopes to Prevent Cardiac-Implantable Electronic Device Infection: Past, Present, and Future. Cureus 13(2): e13088. DOI 10.7759/cureus.13088
Risk factors for CIED infection include both patient and procedural factors and are summarized in Table 1 [6-8].

| Patient factors                                                                 | Procedural factors                                                                 |
|---------------------------------------------------------------------------------|------------------------------------------------------------------------------------|
| Age, previous valvular surgery, device reimplantation, renal failure or dialysis, heart failure, chronic lung disease, cerebrovascular disease, recent fever (≤24 hours), development of hematoma, diabetes, corticosteroid use, oral anticoagulation | Presence of temporary wire, need for re-intervention, use of surgical drains, multiple procedures, type of CIED, duration of the procedure, presence of preexisting transvenous leads (abandoned), length of the procedure |

**TABLE 1: Risk factors for CIED infection**

CIED: cardiac-implantable electronic device.

**Microbiology and pathogenesis of CIED-related infections**

Coagulase-negative Staphylococci (primarily *Staphylococcus epidermidis*) and *S. aureus* account for >70% of all CIED infections (Figure 1) [9]. Less common pathogens include Gram-negative cocci and fungi. The prevalence of antibiotic-resistant Staphylococcus spp. (particularly *S. aureus*) differs based on the study and geographic location of the study population and must be considered when managing CIED infections [2]. Clinical presentation ranges from local infection of the surgical pocket to bacteremia and endocarditis [2]. Majority of CIED-related infections due to contamination of the pocket by skin flora during the initial implantation or subsequent revision procedures. Pocket infection can also occur following erosion of the device or leads through the skin. Infection of the CIED pocket can then propagate along the leads into the intravascular system, resulting in bloodstream infection and valvular endocarditis. Occasionally, patients may develop hematogenous seeding of the electrode or pocket from a distant source [2].

**FIGURE 1: Common microbiology and pathogenesis of CIED-related infections**

CIED: cardiac-implantable electronic device.
host that coat the device surface in the pocket; this mechanism is particularly relevant to new device
technologies, such as CIED envelopes. As additional bacteria attach to the bacteria already adhered to
the device surface, a biofilm of bacterial layers and intercellular adhesins develops, which makes the bacteria
more resistant to antibiotics and immune defenses, specifically by inhibiting penetration to the local area
[2].

Prevention of CIED-related Infections

Standard Prophylaxis (Excluding Antibiotic-Eluting Device Envelopes)

Prophylaxis is the preferred strategy to reduce morbidity and mortality associated with CIED infection
[2]. Evidence-based approaches to reduce infection risk include preoperative administration of antibiotics
and thorough skin antisepsis [2]. Parenteral antibiotics administered prior to implantation procedure have
been shown to significantly reduce the incidence of device-related infections [2,10]. In one double-blind
trial, 649 patients were randomized to IV cefazolin or placebo, both administered immediately before the
procedure [10]. The trial was terminated early due to clear evidence of benefit; infections occurred in 0.63%
of the cefazolin group and 3.28% of the placebo group (relative risk 0.19; P=0.016). Based on this landmark
trial, the American Heart Association recommends the administration of parenteral antibiotics within an
hour of CIED procedures [2].

Skin antisepsis is another standard preoperative technique for reducing CIED infection risk [2]. Some
evidence suggests benefits to the use of chlorhexidine-alcohol over povidone-iodine, mostly based on a
single randomized study of patients undergoing clean-contaminated surgeries, mostly abdominal and
thoracic (not CIED-related). This study reported a significantly lower infection rate with chlorhexidine-
alcohol compared to povidone-iodine (9.5% vs. 16.1%; P=<0.004) [11]. Other common prophylactic techniques
include optimization of the patient’s clinical status, a chlorhexidine scrub (Hibiclens) prior to the procedure,
eradication of nasal bacteria methicillin-resistant S. aureus (MRSA), and irrigation of the surgical pocket
with antibiotics. It is worth noting that evidence does not definitively support their efficacy for the
prevention of CIED infections [12]. Similarly, there is currently no evidence to support the use of
postoperative antibiotics [8]. However, despite the minimal evidence, these strategies are common in
clinical practice. In the large cohort of 6983 patients in the recently reported WARP-IT study, 74.5% received
pocket irrigation with antimicrobial solutions, and 29.6% received post-procedure antibiotics [3].

Antibiotic-Eluting CIED Envelopes

Antimicrobial-impregnated CIED envelopes have been developed to hold devices securely in place to
provide a stable environment and to reduce infection risk [13]. These devices deliver a prolonged, high
concentration of antibiotics effective against common CIED pathogens within the CIED pocket. Because
most CIED contaminations are believed to occur at the time of implantation, these envelopes should provide
an effective method of CIED infection prophylaxis. Evidence from other surgical procedures supports the
efficacy of local antibiotic delivery to prevent wound infections [14-16]. For example, the use of gentamicin-
impregnated collagen implants significantly reduces the risk for sternal wound infections in high-risk
patients undergoing cardiac surgery [15-17]. Studies of this collagen-based technology identified high
gentamicin concentrations at the surgical site and very low serum drug levels, suggesting that antibiotic is
concentrated at the site of potential infection while minimizing systemic exposure and the risk for adverse
events or the development of bacterial resistance [16-19].

Two CIED envelope devices are currently available for use in the US. Both are absorbable. One is made from
absorbable multifilament block copolymer comprised of glycolide, caprolactone, and trimethylene carbonate
mesh that is coated with an absorbable polycrylate polymer containing minocycline and rifampin. The
other envelope is made from decellularized, non-crosslinked ECM, which is derived from porcine intestinal
submucosa; this device is hydrated in a gentamicin solution prior to implantation (Figure 2). These
envelopes are designed to stabilize the CIED within the pocket, limiting the risk for migration or erosion. The
envelopes also provide a substrate for tissue ingrowth and allow for the local delivery of antibiotics.
FIGURE 2: ECM is hydrated in a gentamicin solution prior to implantation

ECM: extracellular matrix.

Synthetic Mesh Envelope

The CIED envelope made of synthetic mesh (TYRX™; Medtronic, Inc., Monmouth Junction, NJ) elutes minocycline and rifampin for a minimum of seven days. An earlier version of the device (AEGIS) consisted of non-absorbable polypropylene but was associated with significant pocket fibrosis, making removal of a generator and/or leads difficult. A newer version was developed that is fully absorbed within approximately nine weeks after implantation. Initial retrospective studies suggested potential benefits to this device, and these findings were further supported by the prospective CITADEL and CENTURION studies [20-22]. Combined analysis of these studies identified a significantly lower CIED-related infection rate among prospectively enrolled patients treated with the synthetic mesh envelope, compared to historical controls (0.4% vs. 2.2%; \( P=0.0023 \)) [22]. A recent meta-analysis of five cohort studies reported a pooled odds ratio of 0.31 (0.17, 0.58, 95% CI, \( P=0.0002 \)) for CIED infection with versus without antibacterial envelopes for CIED implantation [23].

Importantly, the efficacy of the synthetic envelope was recently reported in a prospective multicenter randomized clinical trial (WRAP-IT 2019) [3]. This trial enrolled 6983 patients undergoing CIED implantation, replacement, or revision to receive the synthetic mesh envelope or not (control). Overall, 25 patients in the envelope group and 42 patients in the control group met the primary endpoint (infection resulting in device extraction or revision, long-term antibiotic therapy with infection recurrence, or death) within 12 months of the procedure (12-month estimated event rate 0.7% vs. 1.2%, respectively; \( P=0.04 \)). In addition, long-term follow (36 months) of WRAP-IT study reported major CIED-related infections occurred in 32 envelope patients and 51 control patients (Kaplan-Meier [KM] estimate 1.3% vs. 1.9%; hazard ratio [HR] 0.64; 95% confidence interval [CI] 0.41-0.99; \( P=0.046 \)). Any CIED-related infection occurred in 57 envelope patients and 84 control patients (KM estimate 2.1% vs 2.8%; HR 0.69; 95% CI 0.49-0.97; \( P=0.030 \)). System- or procedure-related complications occurred in 235 envelope patients and 252 control patients (KM estimate 8.0% vs. 8.2%; HR 0.95; 95% CI 0.79-1.13; \( P<0.001 \) for noninferiority) [24].

Although the results of this well-designed study (WRAP-IT) achieved statistical significance (i.e., \( P<0.05 \)), the findings were not as robust as anticipated due to lower than anticipated overall infection rate. Moreover, the number-needed-to-treat (NNT) for this study to prevent one CIED infection was 200 patients, an elevated number compared to other preventive therapies. Therefore, further refinements are needed to optimize the clinical benefits and costs of these novel envelopes.
Another CIED envelope that uses different materials and antibiotics is currently available. The CanGaroo-G™ envelope (Aziyo Biologics, Silver Spring, MD) is made with a biologic material that utilizes ECM, rather than synthetic mesh, to create a bioscaffold for tissue integration and neovascularization (Figure 2). This ECM envelope is made of a four-layer biomaterial derived from decellularized, non-cross-linked porcine intestinal submucosa. Prior to implantation, the ECM envelope is hydrated in a gentamicin solution (20 mL of 40 mg/mL solution) for two minutes. The ECM envelope can be used for transvenous pacemakers as well as subcutaneous implantable cardioverter defibrillators (SICD). Xiang and Levine described the first published clinical procedural use of the SICD envelope to anchor the SICD to the thoracic wall [25]. Preclinical studies suggest that the ECM envelope delivers high concentrations of gentamicin to the surrounding tissues, with minimal systemic exposure, providing excellent efficacy against Staphylococcus spp. and other CIED pathogens [26]. Importantly, the release of gentamicin from the ECM envelope peaks early (within one hour), followed by a gradual, sustained release over one week. This pharmacokinetic profile matches the presumed mechanism of CIED infection, which most often involves contamination of the pocket by skin flora at the time of implantation. In the recently published preclinical animal infection model, no bacteria were recovered from any culture after 12 hours of exposure to the gentamicin containing ECM envelope. Serum gentamicin levels dropped below the limit of quantification at 15 hours after implant [27]. Gentamicin concentration in the ECM envelope remained relatively stable for up to seven days [27]. These findings suggest that gentamicin containing ECM envelope is effective in reducing bacterial burden in the implant pocket.

**Synthetic vs. biologic materials**

Compared with artificial materials, such as synthetic surgical mesh, biologic ECM has been shown to foster greater tissue integration and vascular ingrowth, a reduced inflammatory response, and more rapid clearance of bacteria [28-33]. Numerous studies have demonstrated that ECM-based materials, particularly non-cross-linked materials, promote site-specific functional tissue remodeling [28,29]. Non-cross-linked biologic materials have also been shown to minimize foreign body response, inflammation, and fibrosis and foster angiogenesis and cell differentiation as part of the remodeling process [30,31]. As a result of reduced inflammation and enhanced tissue ingrowth and angiogenesis, these biologic materials can promote the elimination of bacteria and thereby reduce infection risk [32]. Moreover, some studies suggest that ECM bioscaffolds have inherent bactericidal activity [33]. Certain antibacterial factors are active within the intact ECM, whereas others are released during modification of the matrix after implantation. It has been suggested that components of intact ECM promote a transformation in macrophage phenotype from predominantly pro-inflammmatory (called M1) to anti-inflammatory (M2). M1-type macrophages mediate tissue damage and promote an inflammatory response [34]. Infiltration of M2-type macrophages has been shown in the early stages of tissue repair, and depletion of M2-type macrophages has been shown to inhibit the formation of vascularized granulation and scar tissues [35]. Repair materials with different characteristics stimulate differing macrophage responses, and a correlation has been shown between early macrophage response and tissue remodeling outcomes [56]. A greater proportion of M2 macrophages has been associated with positive remodeling outcomes, as occurs with non-cross-linked ECM. In contrast, synthetic materials and highly cross-linked biologic materials typically trigger a more robust foreign body response, including chronic inflammation and fibrous encapsulation of the material, rather than integration into host tissues [28,31]. The inflammatory response to synthetic and cross-linked materials is characterized by a predominance of M1 phenotype, which facilitates the formation of scar tissue and encapsulation of the material [35,37]. Based on this evidence, biologic repair materials are generally preferred over synthetic materials in contaminated surgical fields [38].

**Envelope-delivered antibiotics**

Studies of multiple surgical procedures have reported reduced infection rates with the local application of antibiotics. Based on this evidence, the microbiology of CIED infections, and bactericidal data, current CIED envelope devices utilize either rifampin/minocycline or gentamicin for infection prophylaxis.

**Rifampin and Minocycline**

Rifampin inhibits bacterial DNA-dependent RNA synthesis, whereas minocycline inhibits bacterial protein synthesis. Both agents are active against Staphylococcus spp. [8]. The reported MIC of rifampin for *S. aureus* and coagulase-negative Staphylococci isolated from CIED infections is ~0.5 to 2 mg/L [39]. In vitro studies have demonstrated rifampin has activity against *S. epidermidis* biofilms, especially in combination with certain other agents, whereas many other tested antibiotics were ineffective [40]. The addition of rifampin to minocycline has been shown to potentiate its in vitro antibacterial effect, including on resistant strains such as MRSA [41]. The combination of both drugs also reduces resistance to rifampin [42].

The combination of rifampin/minocycline has been used extensively in antibiotic-impregnated catheters. Studies report significant reductions in the risk for infection with rifampin/minocycline-impregnated catheters compared to standard catheters in neurosurgical procedures [43], chemotherapy administration [44], and other central venous catheter applications [45]. Studies of the synthetic mesh CIED envelope, which elutes a combination of rifampin and minocycline, have demonstrated a reduction in bacterial contamination in rabbit models, including the elimination of Staphylococcus spp., *Escherichia coli*, and other
bacterial species [46]. The aforementioned WRAP-IT study demonstrated significant (P<0.05) reductions in CIED-related infections with the rifampin/minocycline synthetic envelope, compared to no envelope [3].

**Gentamicin**

Gentamicin is an aminoglycoside that inhibits bacterial protein synthesis and has a broad-spectrum bactericidal activity that includes Staphylococcus spp. and aerobic Gram-negative organisms. Susceptibility studies demonstrate >5-log reductions in bacterial colonization (i.e., >99.9% reductions), both in vitro and in vivo including the bacteria most commonly isolated from CIED infections. The minimum inhibitory concentration (MIC) for gentamicin for common CIED pathogens (e.g., Staphylococcus spp.) has been reported to be 0.5 to 4 mg/L [39,47].

Gentamicin has demonstrated efficacy in vitro against Staphylococcal biofilms; in one study, only daptomycin had similar efficacy among single-agent antibiotics [48]. Similarly, an in vitro pharmacodynamic study demonstrated 3-log reductions in *S. aureus* inoculates across a sixfold range of gentamicin concentrations [49].

Some clinical data and animal studies also suggest the antimicrobial efficacy of gentamicin for the prevention of CIED-related infections [27]. Local use of gentamicin has been shown to reduce infection rates in patients undergoing CIED implantation [24,50].

The main limitation of the systemic use of gentamicin is its association with risk for nephrotoxicity and ototoxicity. Consequently, systemic administration of aminoglycosides has been used sparingly for several decades, thereby limiting the development of resistance to this class of antibiotics. Conversely, as described above, local administration of gentamicin has demonstrated efficacy in multiple surgical procedures, without the risks of systemic exposure [15-17,23,50].

The effects of gentamicin are concentration-dependent, requiring a high concentration in the surgical site to produce high bactericidal activity, even against organisms with low susceptibility or resistance to this agent. When administered into the surgical site, gentamicin concentrations in local tissues can exceed 500 mg/L, whereas systemic exposure is limited to ~1-2 mg/L [18]. In one study of sternal wound infection, treatment using a collagen implant loaded with gentamicin was effective, even when antibiotic-resistant *S. epidermidis* was present, presumably due to the high local concentrations of gentamicin [18]. Therefore, local administration of gentamicin using an ECM envelope provides high early tissue concentrations of antibiotics, with minimal systemic exposure.

Currently, the efficacy of gentamicin delivering ECM envelope has been reported in preclinical animal infection models and clinical case report [25,27]. A prospective randomized clinical study is needed to prove the safety and efficacy of CIED infection reduction. It is worth mentioning that a similar preclinical animal model was used earlier to investigate the safety and efficacy of minocycline/rifampin synthetic envelope [46]. The results of such animal experiments were later confirmed in a prospective randomized clinical trial [3].

**Conclusions**

Minimizing risks of adverse outcomes associated with CIED implantation, especially infection, is of paramount importance to prevent serious complications that warrant device removal. New CIED envelope technologies demonstrate promise to reduce generator pocket infection. Preclinical and clinical data support the efficacy of local antibiotic delivery through synthetic or ECM-based CIED envelopes eluting rifampin/minocycline and gentamycin, respectively. Moreover, the ECM envelope typically stimulates tissue remodeling and angiogenesis, thereby minimizing inflammation and promoting bacterial clearance. Large, prospective studies are needed to help refining indications and judicious use of the ECM envelope to prevent CIED infection.

**Additional Information**

**Disclosures**

**Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: *Payment/services info:* All authors have declared that no financial support was received from any organization for the submitted work. *Financial relationships:* John Catanzaro, MD declare(s) personal fees from Aziyo Biologics, Inc. Honoraria/Consulting fee: All Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

**References**

1. Voigt A, Shalaby A, Saba S: Continued rise in rates of cardiovascular implantable electronic device infections in the United States: temporal trends and causative insights. Pacing Clin Electrophysiol. 2010, 33:414-419. 10.1111/j.1540-8159.2009.02569.x
2. Baddour LM, Epstein AE, Erickson CC, et al.: Update on cardiovascular implantable electronic device infections and their management: a scientific statement from the American Heart Association. Circulation. 2010, 121:458-477. 10.1161/CIRCULATIONAHA.109.192665

3. Hillock N, Hillock R, Warner M: Antibacterial envelope to prevent cardiac implantable device infection. N Engl J Med. 2019, 381:1895-1905. 10.1056/NEJMoa1908355

4. Sohail MR, Eby EL, Ryan MP, Gunnarsson C, Wright LA, Greenspon AJ: Incidence, treatment intensity, and incremental annual expenditures for patients experiencing a cardiac implantable electronic device infection: evidence from a large US payer database 1-year post implantation. Circ Arrhythm Electrophysiol. 2016, 9:e003929. 10.1161/CIRCEP.116.003929

5. Greenspon AJ, Patel JD, Lau E, et al.: 16-year trends in the infection burden for pacemakers and implantable cardioverter-defibrillators in the United States 1993 to 2008. J Am Coll Cardiol. 2011, 58:1001-1006. 10.1016/j.jacc.2011.04.033

6. Pruutik M, Reynolds MR, Bao H, Curtis JP, Al-Khatib SM, Aggarwal V, Usalan DZ: Rates of and factors associated with infection in 200,909 Medicare implantable cardioverter-defibrillator implants: results from the National Cardiovascular Data Registry. Circulation. 2014, 130:1037-1045. 10.1161/CIRCULATIONAHA.114.009891

7. Johansen JB, Jorgensen OD, Moller M, Arnbjo M, Mortensen PT, Nielsen JC: Infection after pacemaker implantation: infection rates and risk factors associated with infection in a population-based cohort study of 46299 consecutive patients. Eur Heart J. 2011, 32:991-998. 10.1093/eurheartj/ehq497

8. Gleva MJ, Poole JE: Prevention of cardiac implantable electronic device infections: update and evaluation of the potential role for capsulectomy or the antibiotic pouch. J Arrhythm. 2017, 9:1540. 10.4022/jarrh.1540

9. Sohail MR, Usalan DZ, Khan AH, et al.: Management and outcome of permanent pacemaker and implantable cardioverter-defibrillator infections. J Am Coll Cardiol. 2007, 49:1851-1859. 10.1016/s0735-1097(07)61422-2

10. de Oliveira JC, Martinelli M, Nishioka SA, et al.: Efficacy of antibiotic prophylaxis before the implantation of pacemakers and cardioverter-defibrillators: results of a large, prospective, randomized, double-blinded, placebo-controlled trial. Circ Arrhythm Electrophysiol. 2009, 2:29-34. 10.1161/CIRCEP.108.795906

11. Darouiche RG, Wall MJ, Jr., Itani KM, et al.: Chlorhexidine-alcohol versus povidone-iodine for surgical-site antisepsis. N Engl J Med. 2010, 362:18-26. 10.1056/NEJMoa1009886

12. Vazquez RJ, Ellis CR, Defaye P, Kenneser C: Cardiac implantable electronic device infection in patients at risk. Arrhythm Electrophysiol Rev. 2016, 5:65-71. 10.15420/ser.2015.27.2

13. Huntington life sciences study TR-2011-054. (2011).

14. Chang WK, Sriwivasa S, MacCormick AD, Hill AG: Gentamicin-collagen implants to reduce surgical site infection: systematic review and meta-analysis of randomized trials. Ann Surg. 2015, 258:59-65. 10.1097/SLA.0000000000001340

15. Kovalewski M, Pawlitzak Z, Zaborowska K, et al.: Gentamicin-collagen sponge reduces the risk of sternal wound infections after heart surgery: meta-analysis. J Thorac Cardiovasc Surg. 2015, 149:1631-1640. 10.1016/j.jtcvs.2015.01.054

16. Friberg O, Dahlin LG, Kallman I, Kihlström E, Soderquist B, Svedjeholm R: Collagen-gentamicin implant for prevention of sternal wound infection; long-term follow-up of effectiveness. Ann Thorac Surg. 2009, 88:454-458. 10.1016/j.athoracsur.2009.06.043

17. Friberg O, Svedjeholm R, Soderquist B, Granfeldt H, Vikerfors T, Kallman J: Local gentamicin reduces sternal wound infections after cardiac surgery: a randomized controlled trial. Ann Thorac Surg. 2005, 79:153-161. 10.1016/j.thorac신문.2004.06.043

18. Leyh RG, Bartels C, Sievers HH: Adjuvant treatment of deep sternal wound infection with collagenous gentamycin. Ann Thorac Surg. 1999, 68:1648-1651. 10.1016/s0003-4975(99)00836-x

19. Friberg O, Jones I, Sjögren L, Soderquist B, Vikerfors T, Kallman J: Antibiotic concentrations in serum and wound fluid after local gentamicin or intravenous dicrosucin prophylaxis in cardiac surgery. Scand J Infect Dis. 2003, 35:251-254. 10.1080/0036554031000184

20. Kolek MJ, Dresen WF, Wells QS, Ellis CR: Use of an antibiotic envelope is associated with reduced cardiac implantable electronic device infections in high-risk patients. Pacing Clin Electrophysiol. 2013, 36:534-361. 10.1111/pace.12063

21. Mittal S, Shaw RE, Michel K, et al.: Cardiac implantable electronic device infections: incidence, risk factors, and the effect of the AigisRx antibacterial envelope. Heart Rhythm. 2014, 11:595-601. 10.1016/j.hrthm.2013.12.015

22. Henriksson CA, Sohail MR, Acosta H, et al.: Antibacterial envelope is associated with low infection rates after implantable cardioverter-defibrillator and cardiac resynchronization therapy device replacement: results of the cardiadel and centurion studies. JACC Clin Electrophysiol. 2017, 3:1158-1167. 10.1016/j.jaecp.2017.02.016

23. Koerber SM, Turagam MK, Winterfield J, Gautam S, Gold MR: Efficacy of antibiotic prophylaxis before the implantation of extracardiac-matrix envelope implants with added vancomycin and gentamicin for device implant protection. Pacing Clin Electrophysiol. 2017, 40:615-623. 10.1111/pac.13061

24. Sohail MR, Esquer Garrigos Z, Elyai CS, Xiang K, Kallman J: Preclinical evaluation of efficacy and pharmacokinetisch of gentamicin containing extracellular-matrix envelope. Pacing Clin Electrophysiol. 2020, 43:341-349. 10.1111/pac.13088

25. Cavallo JA, Greco SC, Liu J, Frisella MM, Deeken CR, Matthews BD: Remodeling characteristics and
biomechanical properties of a crosslinked versus a non-crosslinked porcine dermis scaffolds in a porcine model of ventral hernia repair. Hernia. 2015, 19:207-218. 10.1007/s10029-015-1070-2

29. Fallon AM, Goodchild TT, Cox JL, Matheny RG: In vivo remodeling of a novel bioprosthetic tricuspid valve in an ovine model. J Thorac Cardiovasc Surg. 2014, 148:535-540. 10.1016/j.jtcvs.2015.10.048

30. Totrey S, Cornelli M, Jefferies EM, Londono R, Peat B, Badyak LF: Extracellular matrix degradation products and low-oxygen conditions enhance the regenerative potential of perivascular stem cells. Tissue Eng Part A. 2011, 17:37-44. 10.1089/ten.TEA.2010.0188

31. Wolf MT, Carruthers CA, Dearth CL, et al.: Polypropylene surgical mesh coated with extracellular matrix mitigates the host foreign body response. J Biomed Mater Res A. 2014, 102:234-246. 10.1002/jbm.a.34671.

32. Badyak LF, Wu CC, Bible M, McPherson E: Host protection against deliberate bacterial contamination of an extracellular matrix bioscaffold versus Dacron mesh in a dog model of orthopedic soft tissue repair. J Biomed Mater Res B Appl Biomater. 2003, 67:648-654. 10.1002/bbm.b.10062

33. Brennan EP, Reing J, Chew D, Myers-Irvin JM, Young EJ, Badyak LF: Antibacterial activity within degradation products of biological scaffolds composed of extracellular matrix. Tissue Eng. 2006, 12:2949-2955. 10.1089/ten.2006.12.2949

34. Mantovani A, Biswas SK, Galderisi MR, Sica A, Locati M: Macrophage plasticity and polarization in tissue repair and remodelling. J Pathol. 2015, 232:176-185. 10.1002/path.4133

35. Lucas T, Waisman A, Ranjan R, et al.: Differential roles of macrophages in diverse phases of skin repair. J Immunol. 2010, 184:5964-5977. 10.4049/jimmunol.0903556

36. Brown BN, Londono R, Totrey S, et al.: Macrophage phenotype as a predictor of constructive remodeling following the implantation of biologically derived surgical mesh materials. Acta Biomater. 2012, 8:978-987. 10.1016/j.actbio.2011.11.031

37. Delgado LM, Bayon Y, Pandit A, Zeulig DS: To cross-link or not to cross-link? Cross-linking associated foreign body response of collagen-based devices. Tissue Eng Part B Rev. 2015, 21:298-315. 10.1089/ten.TEB.2014.0290

38. Garvey PB, Martinez RA, Baumann DP, Liu J, Butler CE: Outcomes of abdominal wall reconstruction with acellular dermal matrix are not affected by wound contamination. J Am Coll Surg. 2014, 219:853-864. 10.1016/j.jamcollsurg.2014.06.021

39. Wang R, Li X, Wang Q, Zhang Y, Wang H: Microbiological characteristics and clinical features of cardiac implnentable electronic device infections at a tertiary hospital in China. Front Microbiol. 2017, 8:3660. 10.3389/fmicb.2017.00360

40. Gomes F, Teixeira P, Ceri H, Oliveira R: Evaluation of antimicrobial activity of certain combinations of antibiotics against in vitro Staphylococcus epidermidis biofilms. Indian J Med Res. 2012, 135:542-547.

41. Bowker KE, Noel AR, Macgowan AP: Pharmacodynamics of minocycline against Staphylococcus aureus in an in vitro pharmacokinetic model. Antimicrob Agents Chemother. 2008, 52:4572-4573. 10.1128/AAC.00922-07

42. Shiels SM, Tennent DJ, Lofgren AL, Wenke JC: Topical rifampin powder for orthopaedic trauma part II: Topical rifampin allows for spontaneous bone healing in sterile and contaminated wounds. J Orthop Res. 2018, 36:3142-3150. 10.1002/jor.24155

43. Wang X, Dong Y, Qi XQ, Li YM, Huang CG, Hou LJ: Topical rifampin allows for spontaneous bone healing in sterile and contaminated wounds. J Orthop Res. 2018, 36:3142-3150. 10.1002/jor.24155

44. Chemaly RF, Sharma PS, Youssouf S, et al.: The efficacy of catheters coated with minocycline and rifampin in the prevention of catheter-related bacteremia in cancer patients receiving high-dose interleukin-2. Int J Infect Dis. 2010, 14:548-552. 10.1016/j.ijid.2009.08.007

45. Falagas ME, Fragoulis K, Bliziotis IA, Chatzinikolaou I: Rifampcin-impregnated central venous catheters: a meta-analysis of randomized controlled trials. J Antimicrob Chemother. 2007, 59:539-569. 10.1093/jac/dkl322

46. Hansen LK, Brown M, Johnson D, Palme II DF, Love C, Darouiche R: Impact of minimal inhibitory concentration breakpoints on local cumulative bacterial susceptibility data and antibiotic consumption. BMC Res Notes. 2014, 7:605. 10.1186/1756-0500-7-605

47. Dall GF, Tsang SJ, Gwynne PJ, et al.: Unexpected synergistic and antagonistic antibiotic activity against Staphylococcus biofilms. J Antimicrob Chemother. 2018, 73:1830-1840. 10.1093/jac/dky087

48. Schafer JA, Hovde LB, Rotschafer JC: Consistent rates of kill of Staphylococcus aureus by gentamicin over a 6-fold clinical concentration range in an in vitro pharmacodynamic model (IPVDM). J Antimicrob Chemother. 2006, 58:108-111. 10.1093/jac/dkl216

49. Futyma PR, Gluszczyz R, Ciapala K, Futyma M: Zero device-related infections in 4285 patient-years of follow-up of cardiac implantable electronic device replacement combined with topic gentamicin-collagen sponge application. EP Europace. 2017, 19:506. 10.1093/epca/evx158.125